X

Drug Profile

AVE 0657

Alternative Names: AVE-0657

Latest Information Update: 05 May 2009

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator sanofi-aventis
Class Sleep disorder therapies
Mechanism of Action Sodium-hydrogen antiporter inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Respiration disorders; Sleep apnoea syndrome

Most Recent Events

29 Apr 2009 Discontinued - Phase-II for Respiration disorders in European Union (PO)
29 Apr 2009 Discontinued - Phase-II for Sleep apnoea syndrome in European Union (PO)
13 Feb 2007 Phase-I clinical trials in Sleep apnoea syndrome in European Union (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com